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Abstract
Background: SRY (sex-determining region Y)-box 2 (SOX2) is a crucial transcription factor for the maintenance of embryonic
stem cell pluripotency and the determination of cell fate. Previously, we demonstrated that SOX2 plays important roles in
growth inhibition through cell cycle arrest and apoptosis, and that SOX2 expression is frequently down-regulated in gastric
cancers. However, the mechanisms underlying loss of SOX2 expression and its target genes involved in gastric
carcinogenesis remain largely unknown. Here, we assessed whether microRNAs (miRNAs) regulate SOX2 expression in
gastric cancers. Furthermore, we attempted to find downstream target genes of SOX2 contributing to gastric
carcinogenesis.
Methodology/Principal Findings: We performed in silico analysis and focused on miRNA-126 (miR-126) as a potential SOX2
regulator. Gain- and loss-of function experiments and luciferase assays revealed that miR-126 inhibited SOX2 expression by
targeting two binding sites in the 39-untranslated region (39-UTR) of SOX2 mRNA in multiple cell lines. In addition, miR-126
was highly expressed in some cultured and primary gastric cancer cells with low SOX2 protein levels. Furthermore,
exogenous miR-126 over-expression as well as siRNA-mediated knockdown of SOX2 significantly enhanced the anchorage-
dependent and -independent growth of gastric cancer cell lines. We next performed microarray analysis after SOX2 over-
expression in a gastric cancer cell line, and found that expression of the placenta-specific 1 (PLAC1) gene was significantly
down-regulated by SOX2 over-expression. siRNA- and miR-126-mediated SOX2 knockdown experiments revealed that miR-
126 positively regulated PLAC1 expression through suppression of SOX2 expression in gastric cancer cells.
Conclusions: Taken together, our results indicate that miR-126 is a novel miRNA that targets SOX2, and PLAC1 may be a
novel downstream target gene of SOX2 in gastric cancer cells. These findings suggest that aberrant over-expression of miR-
126 and consequent SOX2 down-regulation may contribute to gastric carcinogenesis.
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Introduction
The SOX2 gene encodes a member of the SRY-related HMG-
box (SOX) family of transcription factors involved in the regulation
of embryonic development and in the determination of cell fate
[1,2,3]. In particular, it is well known that SOX2 plays important
roles in maintenance of embryonic stem (ES) cell self-renewal and
pluripotency [4,5]. Among adult tissues, SOX2 is expressed in the
brain, retina, tongue, lung, esophagus and stomach, and plays
crucial roles in the differentiation and morphogenesis of these
organs [6,7,8]. We previously reported that SOX2 mRNA and
protein were expressed in normal gastric mucosae, but frequently
down-regulated in human gastric cancer tissues and cell lines, some
of which are due to aberrant DNA methylation [9,10]. We further
revealed that SOX2 plays important roles in growth inhibition
through cell cycle arrest and apoptosis, indicating that SOX2 may
have tumor-suppressive functions in gastric cancer cells [10].
However, the downstream target genes of SOX2 involved in gastric
carcinogenesis remain largely unknown.
MicroRNAs (miRNAs) are small, approximately 22-nucleotide,
noncoding RNAs that regulate the expression of hundreds of genes
by targeting their mRNAs posttranscriptionally [11]. miRNAs
bind to the partially complementary target sites in 39-untranslated
regions (39-UTRs) of mRNAs, inducing direct mRNA degradation
or translational inhibition [11]. To date, it has been reported that
the miRNA expression profiles differ between in normal tissues
and derived tumors, including gastric cancer, and many miRNAs
can act as tumor suppressors or oncogenes [12,13,14]. Recently, it
was reported that miRNA-134 and miRNA-145 repress SOX2
expression by targeting its coding region in mouse ES cells and the
39-UTR in human ES cells, respectively [15,16]. However, there
have been no reports on miRNA(s) that can regulate SOX2
expression in human gastric cancer.
In the initial step of this study, we performed immunohisto-
chemical analysis of the SOX2 protein in human gastric cancer
tissues, in which the DNA methylation statuses of SOX2 had
already been examined [10], and found that a certain number of
SOX2 expression-negative cases did not show DNA hypermethy-
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underlying SOX2 down-regulation. Accordingly, in this study, we
aimed to find miRNAs that target SOX2 expression in human
gastric cancers. We found that miRNA-126 (miR-126) repressed
SOX2 expression by targeting its 39-UTR, and then performed
functional analyses of miR-126 in gastric cancer cells. To further
clarify the importance of miR-126-mediated SOX2 down-
regulation in gastric carcinogenesis, we attempted to identify
downstream target genes of SOX2 in gastric cancer cells.
Results
The SOX2 39-UTR is a predicted target of miRNA-126 and
-522
In order to find novel miRNAs that regulate SOX2 expression
in gastric cancer, we performed computational analysis using a
miRNA target database, MicroCosm Targets (formerly miRBase
Targets), and tried to identify miRNAs that target the SOX2 39-
UTR according to the following criteria. Considering the position,
number, and sequence conservation of miRNA target sites among
species, we selected two miRNAs, miR-126 and miR-522, as
potential miRNAs targeting the SOX2 39-UTR (Figure 1). miR-
126 has two predictive target sites, which are both near the stop
codon of the SOX2 open reading frame (ORF) in the 39-UTR,
whereas the predicted target site of miR-522 is highly conserved in
seven species and also located near the SOX2 ORF stop codon in
the 39-UTR (Figure 1).
miR-126 inhibits SOX2 expression in multiple cell lines
To validate the results of computational analysis, we examined
whether or not miR-126 and miR-522 can repress the expression
level of the endogenous SOX2 protein in SOX2-expression-
positive gastric cancer cell lines. As shown in the upper panel of
Figure 2A, transfection of the miR-126 mimic molecule (Pre-miR-
126) as well as SOX2 siRNA markedly reduced the endogenous
SOX2 protein level compared with a non-specific negative control
oligonucleotide (NC) in HSC43 cells, but the miR-522 mimic
molecule (Pre-miR-522) did not.
To generally evaluate the possibility that miR-126 inhibits
SOX2 expression, we transfected Pre-miR-126 and Anti-miR-126
inhibitor (Anti-miR-126) into multiple gastric cancer cell lines. We
used the following cell lines for transient transfection experiments:
MKN45 (SOX2 positive; miR-126 intermediate) and
TGBC11TKB (SOX2 positive; miR-126 negative) for Pre-miR-
126 transfection; and HSC43 (SOX2 positive; miR-126 positive)
and NUGC3 (SOX2 very low; miR-126 positive) for Anti-miR-
126 transfection (Table 1). Remarkable reductions of the SOX2
protein level were observed in Pre-miR-126-transfected MKN45
and TGBC11TKB cell lines (Figure 2A). Conversely, Anti-miR-
126 transfection up-regulated the SOX2 protein levels in both the
HSC43 and NUGC3 cell lines (Figure 2A), indicating that not
only exogenous Pre-miR-126 but also endogenous miR-126 can
regulate SOX2 protein levels in gastric cancer cells. We also
performed quantitative real-time RT-PCR analysis of SOX2
mRNA expression, and found that exogenous miR-126 modestly
but significantly suppressed the SOX2 mRNA level in HSC43 cells
(Figure 2B).
Because the SOX2 protein is known to be abundantly expressed
in ES cells, we examined whether or not miR-126 inhibits SOX2
protein expression in a mouse ES cell line (SOX2 positive; miR-
126 negative). Interestingly, exogenous miR-126 transfection dose-
dependently decreased the SOX2 protein level in the mouse ES
cells (Figure 2A), suggesting that miR-126 represses SOX2
expression in various species and cell lineages.
miR-126 directly targets the SOX2 39-UTR through two
predicted binding sites
To determine whether or not the predicted target sites for the
miRNAs in the 39-UTR of SOX2 mRNA are responsible for the
SOX2 down-regulation, we performed luciferase reporter assays
with a vector containing the SOX2 39-UTR downstream of the
luciferase reporter gene. As shown in Figure 3A, significant
repression of luciferase activities were observed in HEK293T cells
co-transfected with the pGL4-SOX2 39-UTR vector and Pre-miR-
126 or siRNA that targets the SOX2 39-UTR (Figure 1). On the
other hand, Pre-miR-522 had no significant effect on the luciferase
Figure 1. Schematic diagrams of predicted target sites of miR-126 and miR-522 in the SOX2 39-UTR. The predicted binding sites of miR-
126 and miR-522 are indicated (arrowheads) in the SOX2 39-UTR (1119 bp). The first nucleotide after the stop codon of SOX2 is defined as ‘‘1’’, and the
start- and end-positions of the complementary sequence between SOX2 and miRNAs are indicated above or beneath the arrowheads. *The
horizontal bar below the SOX2 39-UTR indicates the region targeted by the SOX2 siRNA. Sequence alignments of miR-126 and miR-522 with their
corresponding potential target sites in the SOX2 39-UTR are presented in each rectangle. The conservation status among species of the predicted
binding sites is also indicated in each rectangle.
doi:10.1371/journal.pone.0016617.g001
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(Figure 3A). These results, combined with those of Western blot
analysis, indicate that miR-126 is a more potential candidate
miRNA that represses SOX2 expression in gastric cancer than
miR-522.
To examine the direct interaction of miR-126 with the potential
target sites in the SOX2 39-UTR, we carried out luciferase reporter
assays with the deletion mutant vector as to the putative miR-126
target sites. As shown in Figure 1, miR-126 has two predicted
binding sites, A and B, in the 39-UTR of SOX2 mRNA. We
therefore performed luciferase assays with the wild type pGL4-
SOX2 39-UTR vector (Wt), the vectors with each predicted miR-
126 target site deleted, A (Del-A), B (Del-B), or both sites, AB (Del-
AB). Intriguingly, each single deletion mutant vector exhibited a
low inhibitory effect on luciferase activity compared with the Wt
vector after Pre-miR-126 co-transfection (Figure 3B). Moreover,
the double deletion mutant vector, Del-AB, showed complete
reversal of the inhibitory effect of the Pre-miR-126 co-transfection
(Figure 3B), indicating that miR-126 directly inhibits SOX2
expression by targeting the two binding sites in the 39-UTR of
SOX2 mRNA independently.
The inverse correlation between miR-126 and SOX2
expression in some cultured and primary gastric cancer
cells
To assess the relationship between miR-126 and SOX2
expression in gastric cancers, we initially examined SOX2 mRNA
Figure 2. Effects of miR-126 and miR-522 on SOX2 expression. (A) Western blot analysis of SOX2 protein expression after transfection of a
negative control oligonucleotide (NC), Pre-miR-126 (126), Pre-miR-522 (522), SOX2 siRNA (siR), and Anti-miR-126 (A126) in the indicated gastric cancer
cell lines and mouse ES cells. The final concentrations were 50 nM for Pre-miRNAs and siRNA, and 100 nM for Anti-miR-126, respectively. a-tubulin
expression was used as a protein loading control. (B) Quantitative real-time RT-PCR analysis of SOX2 mRNA expression after transfection of the
negative control, Pre-miR-126 and SOX2 siRNA into HSC43 cells. The expression levels were normalized against internal GAPDH expression. The assays
were performed in triplicate, and the bars indicate s.d. *P,0.05.
doi:10.1371/journal.pone.0016617.g002
Table 1. Expression of SOX2 and miR-126 in gastric cancer
cell lines.
SOX2
a
Cell line Protein mRNA miR-126
b
TGBC11TKB +++ +++ -
HSC43 ++ +++ +++
MKN45 ++ +++ +
KATOIII + +++ -
AGS + +++ -
HSC44PE 6 ++ 6
NUGC3 6 ++ +
GCIY - 6 ++
NUGC4 - - ++
HSC58 - - +++
aClassification of band intensity: -, completely invisible; 6, faintly visible; +,
visible; ++, clearly visible; +++, strongly visible.
bmiR-126 expression was measured with TaqMan and calculated by the delta-
delta Ct method using RNU6B as an internal control. The intensity of miR-126
to RNU6B was defined as follows: -, ,0.05; 6, 0.05,0.09; +,0 . 1 ,0.79; ++,
0.8,2.0; +++, .2.0.
doi:10.1371/journal.pone.0016617.t001
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respectively, in 10 gastric cancer cell lines without DNA
methylation of SOX2 (Table 1) [10]. Five of the 10 cell lines
showed low or undetectable levels of the SOX2 protein, whereas
three of them exhibited a low SOX2 mRNA level (Table 1). We
subsequently examined miR-126 expression by TaqMan real-time
PCR analysis in these 10 gastric cancer cell lines. Four (NUGC3,
GCIY, NUGC4 and HSC58) of the 10 cell lines, whose SOX2
mRNA and protein levels were low, exhibited relatively high
expression of miR-126, whereas the other cell lines, except for
HSC43 cells, exhibited relatively low expression of miR-126 and a
high SOX2 mRNA level (Table 1). These data indicate that the
miR-126 expression level is mostly opposite to the SOX2 mRNA
and protein levels in gastric cancer cell lines.
To further compare the expression pattern of miR-126 with that
of SOX2 in primary gastric cancers, we initially examined the
expression levels of SOX2 protein in 15 primary gastric cancer
tissue samples without DNA methylation of SOX2 by immunohis-
tochemistry. We found that almost all non-cancerous mucosae
showed SOX2-positive signal only in the cell nuclei within the
neck of the gastric glands (Figure 4A), whereas nine of the 15 cases
exhibited low or undetectable levels of the SOX2 protein
compared with the paired non-cancerous mucosae (Figure 4).
Next, total RNA was isolated from these 15 gastric cancers and
paired non-cancerous tissues, and the miR-126 expression levels
were determined by TaqMan real-time PCR analysis. Four of the
15 cases exhibited significantly high levels of miR-126 expression,
whereas three of them did low miR-126 levels in comparison with
the adjacent non-cancerous mucosae (Figure 4B). Among the miR-
126-up-regulated cases, three (FG6, FG21 and FG24) exhibited
lower levels of SOX2 protein than paired non-cancerous mucosae
(Figure 4B), suggesting that high levels of miR-126 expression
contribute to low levels of SOX2 protein at least in some primary
gastric cancers. There was no significant correlation between the
miR-126 expression and sex, age, depth of tumor invasion or
histological type (data not shown).
miR-126 enhanced anchorage-dependent and -
independent growth of gastric cancer cells
We next evaluated the effect of miR-126 on tumor cell growth.
We initially examined the proliferation rates of SOX2-expression
positive gastric cancer cell lines, MKN45 and HSC43, after
transient transfection of Pre-miR-126. As shown in Figure 5A, the
Pre-miR-126-transfected-MKN45 and HSC43 cells exhibited
significant growth advantages compared with the control NC-
transfected-cells. Moreover, the SOX2 siRNA-transfected-
MKN45 cells, but not HSC43 cells, significantly increased
proliferation compared with the control cells (Figure 5A),
suggesting that miR-126-mediated growth stimulation may occur
in a SOX2-dependent manner, at least in MKN45 cells.
To determine the role of miR-126 in gastric tumorigenesis, we
next carried out soft agar colony formation assays of gastric cancer
cell lines after Pre-miR-126 transfection (Figure 5B and C). As
shown in Figure 5B, the Pre-miR-126- and SOX2 siRNA-
transfected-MKN45 cells formed larger colonies than the NC-
transfected cells in soft agar at 9 days after transfection. We then
performed soft agar colony formation assays using a CytoSelect
TM
96-Well In Vitro Tumor Sensitivity Assay Kit, which can be used
Figure 3. Interaction between miR-126 and its binding sites in the SOX2 39-UTR. (A) Dual luciferase assay with the pGL4-SOX2 39-UTR
(1050 bp) reporter vector (Wt). 30 nM Pre-miRNAs or SOX2 siRNA, which targets the SOX2 39-UTR, was co-transfected with 10 ng of the indicated
reporter vector into HEK293T cells. (B) Dual luciferase assay with cotransfection of 10 ng of the reporter vectors containing the wild type SOX2 39-UTR
(Wt), single deletion mutant A (Del-A), single deletion mutant B (Del-B), or double deletion mutant AB (Del-AB), and 30 nM negative control or Pre-
miR-126 in HEK293T cells. The assays were performed in triplicate, and the bars indicate s.d. *P,0.05; **P,0.01; n.s., not significant.
doi:10.1371/journal.pone.0016617.g003
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method, such as the WST-8 assay, making the assays quick and
accurate. Exogenous miR-126 over-expression as well as SOX2
siRNA transfection significantly enhanced the anchorage-inde-
pendent colony formation of MKN45 and HSC43 cells compared
with the control cells at 9 to 10 days after transfection, respectively
(Figure 5C). These results suggest that miR-126 may promote the
tumorigenicity of gastric cancer cells through suppression of
SOX2 expression.
miR-126 controls novel SOX2 target genes in gastric
cancer cells
To further understand the potential effects of miR-126-
mediated SOX2 down-regulation on the gene expression change
in gastric cancer cells, we first attempted to identify candidate
downstream target genes of SOX2. We transiently expressed
exogenous SOX2 in NUGC3 cells by using an adenovirus system,
and changes in expression were determined by cDNA microarray
analysis (GEO accession No. GSE23589). Among 41,174 probes,
366 known genes were up-regulated (.2.0-fold) and 369 known
genes were down-regulated (,0.5-fold) by SOX2-over-expression
in NUGC3 cells compared with in control GFP-over-expressing
cells (Table S1). Representative microarray results are summarized
in Table 2, and we found the significant up-regulation of
exogenous SOX2 (.20.20-fold), supporting the validity of this
experiment. Intriguingly, there were many cancer-related genes
that could be novel downstream targets of SOX2 (for example,
LTF, PPP2R1B, TGFBR2, SERPINE1, MMP9, HMGA1, SOX9 and
PLAC1), and squamous cell differentiation markers KRT6E and
KRT6C, whose amino acid sequences are highly conserved among
the KRT6 family members and virtually identical to one of the
known SOX2 downstream genes, KRT6A (Table 2 and Table S1)
[17]. We validated the microarray results by RT-PCR analysis in
NUGC3 cells after SOX2 over-expression, and representative
results are shown in Figure 6A. Most of these genes also showed
changes in their expression after SOX2 over-expression at least in
one more gastric cancer cell line among the two to three cell lines
we investigated (data not shown).
To determine the target genes of SOX2 controlled by miR-126
in gastric cancer cells, we next performed SOX2 knockdown
experiments and further screened for candidate target genes.
SOX2 knockdown by Pre-miR-126 and siRNA was confirmed by
Western blot analysis in SOX2-expression-positive gastric cancer
cell lines MKN45 and HSC43 (Figure 2A), and the subsequent
expression changes of the putative SOX2 downstream target genes
were preliminarily analyzed by RT-PCR in these cell lines, and
then by quantitative real time RT-PCR in HSC43 cells. Among
over 20 cancer-related genes we investigated, only two showed
changes in expression after SOX2 knockdown (data not shown).
First, differentiation marker KRT6A expression, which was up-
regulated by SOX2 over-expression, was significantly down-
regulated by Pre-miR-126 as well as SOX2 siRNA transfection
in HSC43 cells (Figure 6B). Second, placenta- and tumor-specific
PLAC1 expression, which was down-regulated by SOX2 over-
Figure 4. Expression of SOX2 and miR-126 in human gastric cancer tissues. (A) Representative immunohistochemical staining of SOX2
protein in non-cancerous mucosa (Non-Ca) and gastric cancers (FG2 Ca and FG21 Ca). Original magnification: 6400. (B) Quantitative TaqMan real-
time PCR analysis for miR-126 was carried out by using the 15 human gastric cancer tissues (filled bars) and paired non-cancerous tissues (open bars).
The expression levels of cancer tissues were independently compared to those of paired non-cancerous tissues, which are normalized to 1, and the
bars indicate s.d. *P,0.05. The intensities of SOX2 expression were indicated beneath each case by x-axis. The expression levels were determined by
the following criteria: ‘‘++’’ for 10% or more cancer cells were strongly stained; ‘‘+’’ for 10% or more cancer cells were stained; ‘‘w+’’ for less than 10%
cancer cells were weakly stained; ‘‘–’’ for almost all cells were negatively stained.
doi:10.1371/journal.pone.0016617.g004
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with Pre-miR-126 and siRNA in HSC43 cells (Figure 6B). These
results indicate that miR-126 can control KRT6A and PLAC1
expression by down-regulating SOX2 expression in gastric cancer
cells, and these genes might be downstream target genes of SOX2
contributing to gastric carcinogenesis.
Discussion
We previously reported that SOX2 expression was frequently
down-regulated in human gastric carcinoma tissues (about half of
the total cases), some of which was due to aberrant DNA
methylation (about 16% of the total cases) [10]. Therefore, the
mechanisms underlying loss of SOX2 expression have not yet
been defined in more than half of the cases. In this study, we
demonstrated that miR-126 decreased the SOX2 mRNA and
protein expression levels in gastric cancer cell lines. In addition, we
found that miR-126 expression was inversely correlated with
SOX2 expression in certain cultured and primary gastric cancer
cells without DNA methylation of SOX2, indicating that aberrant
miR-126 expression may be a novel mechanism underlying SOX2
down-regulation in gastric cancer. Furthermore, Pre-miR-126
over-expression promoted anchorage-dependent and -indepen-
dent growth of gastric cancer cells in vitro, and increased oncogenic
PLAC1 expression in a gastric cancer cell line. These findings
suggest that miR-126 may be an oncogenic miRNA that controls
SOX2 expression in gastric cancer cells. Besides gastric cancer,
Pre-miR-126 over-expression reduced the SOX2 protein level in
mouse ES cells, suggesting that miR-126 may generally control
SOX2 expression, at least in two species (human and mouse) and
various cell lineages, including ES cells.
MiR-126 is known as an endothelium-specific miRNA, and has
been reported to promote angiogenesis by targeting SPRED1 and
PIK3R2, which normally inhibit VEGF signaling [18,19,20].
Moreover, it has been reported that miR-126 inhibits apoptosis
of acute myeloid leukemia (AML) cells and enhanced the colony-
forming ability of mouse bone marrow progenitor cells through
targeting Polo-like kinase 2 (PLK2), a tumor suppressor [21]. On
the contrary, miR-126 has also been reported to be a tumor
suppressive miRNA, inhibiting tumor cell growth through
Figure 5. Effects of miR-126 expression on anchorage-dependent and -independent cell growth. (A) In vitro cell proliferation assays after
SOX2 knockdown by Pre-miR-126 or siRNA in gastric cancer cell lines. The number of viable cells was determined with a Cell Counting Kit-8 on days 1,
3, 5 and 7 after plating. (B) Representative phase contrast microphotographs of the colonies of MKN45 cells in soft agar at 9 days after transfection of
the negative control, Pre-miR-126 or SOX2 siRNA. Original magnification: 6100. (C) Soft agar colony formation assays for measurement of the
anchorage-independent growth of gastric cancer cell lines. The vertical axis (Absorbance) indicates the relative number of colony-forming cells, which
was determined by the colorimetric assay method. The assays were performed in quadruplicate, and the bars indicate s.d. *P,0.05; **P,0.01.
doi:10.1371/journal.pone.0016617.g005
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HEK293 and MCF-7 cells, respectively [22,23]. Although it is
controversial as to whether miR-126 is a tumor suppressive or
oncogenic miRNA, at least in the present study, we demonstrated
that miR-126 acts as an oncogene by targeting SOX2 in gastric
cancer cells. These functional differences in oncogenesis might be
considered to be a ‘‘lineage-dependency model for cancer’’, that is,
developmentally important genes also have crucial roles during
tumor progression in lineage-specific manners [24]. However,
further studies are needed to clarify the biological roles of miR-126
in gastric carcinogenesis and other tissues.
The initial computational analysis indicated that both miR-126
and miR-522 are candidate miRNAs that target the SOX2 39-
UTR. However, miRNA over-expression experiments showed
that Pre-miR-126 but not Pre-miR-522 reduced SOX2 protein
levels and SOX2 39-UTR luciferase activity. Moreover, loss-of-
function experiments and reporter assays involving deletion
mutants of SOX2 39-UTR luciferase vectors revealed that miR-
126 directly targets the 39-UTR of SOX2. This difference between
miR-126 and miR-522 as to SOX2 regulation is likely to be due to
the following reasons. First, the 59 region, which is called the
miRNA ‘‘seed’’ sequence (nucleotides 2–7), of miR-126 completely
matches the 39-UTR of SOX2, whereas miR-522 does not. It is
well known that perfect ‘‘seed’’ pairing is required for both target
site recognition and repression of the target transcript [25,26].
Second, miR-126 has two binding sites in the 39-UTR of SOX2
mRNA, but miR-522 has only one. It has been reported that when
a miRNA has multiple binding sites in the 39-UTR of its target
gene, the binding sites could be simultaneously targeted by the
miRNA [27,28]. These findings combined with our present data
suggest that the presence of multiple complementary target sites
and perfect matches between these ones and miRNA ‘‘seed’’
region are good indicators for finding functional miRNAs.
In this study, miR-126 expression was found to be relatively
high in SOX2-expression-negative gastric cancer cell lines, and
was aberrantly up-regulated in some primary gastric cancer cases
compared with the paired non-cancerous mucosae. However, the
mechanism underlying this aberrant miR-126 expression in gastric
cancer remains to be elucidated. It was previously reported that
the over-expression of miR-126 in a kind of AML, core-binding
factor (CBF)-AML, is associated with partial demethylation of the
CpG island but not with amplification or mutation of the genomic
locus [21,29]. In fact, we observed that some gastric cancer cell
lines exhibited restored miR-126 expression after treatment with a
demethylating agent, 5-aza-29-deoxycytidine (data not shown).
These findings indicate that miR-126 expression may be
epigenetically regulated in gastric cancer cells.
We performed cDNA microarray analysis to identify the
downstream target genes of SOX2 in gastric cancer cells, and
found that many tumor-associated genes exhibited significant
changes in expression after SOX2-overexpression (e.g., LTF,
PPP2R1B, TGFBR2, SERPINE1, MMP9, HMGA1 and SOX9).
Furthermore, most of them also exhibited changes in their
expression after SOX2-overexpression, at least in two gastric
cancer cell lines. These results indicate that SOX2 might regulate
the expression of these tumor-associated genes, thereby contrib-
Table 2. Representative results of microarray analysis by SOX2 over-expression.
Gene symbol Gene name Fold change
SPP1 secreted phosphoprotein 1 (osteopontin) 63.54
SOX2 SRY (sex determining region Y)-box 2 20.20
IL1R2 interleukin 1 receptor, type II 12.53
KRT6E keratin 6C (virtually identical to KRT6A) 10.52
LTF lactotransferrin 7.85
GSN gelsolin (amyloidosis, Finnish type) 5.97
KRT6C keratin 6C (virtually identical to KRT6A) 7.07
PPP2R1B protein phosphatase 2 regulatory subunit A beta isoform 3.86
KLK10 kallikrein-related peptidase 10 3.24
EPB41L1 erythrocyte membrane protein band 4.1-like 1 2.81
PRKAR2B protein kinase, cAMP-dependent, regulatory, type II, beta 2.75
TGFBR2 transforming growth factor, beta receptor II (70/80kDa) 2.73
SOCS1 suppressor of cytokine signaling 1 2.57
APAF1 apoptotic peptidase activating factor 1 2.22
IL7R interleukin 7 receptor 0.13
SERPINE1 serpin peptidase inhibitor, clade E, member 1 (PAI-1) 0.15
MMP9 matrix metallopeptidase 9 0.27
PLAC1 placenta-specific 1 0.28
PDZK1IP1 PDZK1 interacting protein 1 0.29
SERPINB2 serpin peptidase inhibitor, clade B, member 2 (PAI-2) 0.32
HMGA1 high mobility group AT-hook 1 0.37
SERPINA5 serpin peptidase inhibitor, clade A, member 5 (PAI-3) 0.38
H19 H19, imprinted maternally expressed untranslated mRNA 0.42
SOX9 SRY (sex determining region Y)-box 9 0.47
doi:10.1371/journal.pone.0016617.t002
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significant changes in expression of these genes after SOX2
knockdown by Pre-miR-126 or siRNA, at least in the cell lines we
tested. There are some possible reasons for this discrepancy. First,
it has been reported that a different expression level of SOX2
switches the regulation of target gene expression from up- to
down-regulation, or vice versa [30,31]. In this study, the
expression levels of SOX2 were quite different among the cell
lines that were used for the over-expression and knockdown
experiments. Second, it is well known that stem cell transcription
factors, such as SOX2, OCT3/4 and Nanog, cooperatively
interact with their target genes’ promoters and control their gene
expression, being so-called ‘‘transcriptional cofactors’’. These
expression differences and/or transcriptional cofactors might also
be critical for control of expression of the downstream target genes
of SOX2 in gastric cancer cells, and further studies are necessary
to clarify the roles of SOX2 in the regulation of its target genes.
Expression of KRT6A and PLAC1 was significantly changed by
both SOX2 over-expression and knockdown, suggesting that
SOX2 is the critical regulatory factor for these two genes in gastric
cancer cells. KRT6A is a member of the cytokeratin gene family,
and recently it was reported that ectopic SOX2 over-expression
up-regulated the KRT6A mRNA level in a lung adenocarcinoma
cell line [17]. In the present study, we demonstrated the possibility
that KRT6A expression is also positively regulated by SOX2 in
gastric cells, but the role of KRT6A in gastric carcinogenesis
remains unclear. Thus, further investigations are necessary to
elucidate the roles of KRT6A in gastric carcinogenesis.
On the other hand, PLAC1, a recently described X-linked gene
exhibiting expression restricted to the placenta, is also expressed in
a wide variety of human cancers, including gastric cancer [32,33].
Koslowski et al. reported that siRNA-mediated knockdown of
PLAC1 decreased cell motility, migration and invasion, and
induced G1-S cell cycle arrest with nearly complete abrogation of
proliferation in breast cancer cell lines [34]. In this study, we
demonstrated that SOX2 negatively regulates PLAC1 expression
in gastric cancer cell lines, and propose a novel hypothesis that
miR-126 inhibits SOX2 expression and consequent changes in the
expression of some SOX2 target genes, such as PLAC1, thereby
contributing to gastric carcinogenesis.
In conclusion, for the first time, we demonstrated that miR-126 is
a novel oncogenic miRNA, which targets SOX2, and that
downstream pro-oncogenic target genes of SOX2, such as PLAC1,
may contribute to gastric carcinogenesis. These findings have
important implications for not only explaining the loss of SOX2
expression in gastric cancers, but also for understanding the
transcriptional regulatory mechanisms of SOX2 in other various
cell lineages, such as ES cells. Taken together, our findings may lead
Figure 6. Expression changes of predicted SOX2 target genes. (A) Changes in gene expression after adenovirus-mediated ectopic SOX2 over-
expression in NUGC3 cells. RT-PCR analysis was performed to validate the cDNA microarray results for Ad-GFP-infected (G) and Ad-SOX2-infected
NUGC3 cells (S). GAPDH expression was used as an internal loading control. (B) Quantitative real-time RT-PCR analysis of the KRT6A and PLAC1 mRNA
expression levels after SOX2 knockdown by Pre-miR-126 or siRNA in HSC43 cells. The expression levels were normalized against internal GAPDH
expression. The assays were performed in triplicate, and the bars indicate s.d. **P,0.01.
doi:10.1371/journal.pone.0016617.g006
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provide new insights into the transcriptional regulation of SOX2.
Materials and Methods
Ethics Statement
Written informed consent was obtained from all subjects, and
the study was approved by the Ethics Committee of Tokyo
Medical and Dental University.
Cell lines and tissue samples
We used 10 human gastric cancer cell lines (HSC43, MKN45,
TGBC11TKB, NUGC3, KATOIII, AGS, HSC44PE, GCIY,
NUGC4 and HSC58) and one human embryonic kidney cell line
(HEK293T) in this study, as described previously [10,35]. All the
cell lines were cultured in appropriate medium. Mouse ES cell line
BL6 was obtained from Dr. Hirobumi Teraoka (Tokyo Medical
and Dental University Medical Research Institute, Japan), and was
cultured as described previously [36]. A total of 16 primary gastric
carcinoma tissue samples and corresponding non-cancerous
gastric mucosae were obtained, as described previously [10].
miRNA mimic and inhibitor transfection
Gastric cancer cells were transfected with Precursor Molecules
mimicking miR-126 (Pre-miR-126), miR-522 (Pre-miR-522)
(Applied Biosystems, Foster City, CA), SOX2 siRNA (sense, 59-
GGAAUGGACCUUGUAUAGAUC-39; and anti-sense, 59-UC-
UAUACAAGGUCCAUUCCCC-39, Sigma-Aldrich, St. Louis,
MO), anti-miR inhibitor miR-126 (Anti-miR-126) (Dharmacon,
Lafayette, CO), or scrambled sequence miRNA (Pre-miR-NC)
(Pre-miR Negative Control #1, Applied Biosystems) to give a final
concentration of 10 to 100 nmol/L (nM) by using MicroPorator
MP-100 (Digital BioTechnology, Seoul, Korea), according to the
manufacturer’s instructions. At 24–72 h after transfection, cells
were harvested for Western blot or RT-PCR analyses.
Western blot
Western blot analyses were performed as described previously
[10]. The primary antibodies used were rabbit anti-SOX2
(1:1000: Cell Signaling Technology, Danvers, MA) and mouse
anti-a-tubulin (1:200; Santa Cruz Biotechnology, CA). The
secondary antibodies used were alkaline phosphatase-conjugated
anti-mouse IgG or anti-rabbit IgG (1:2000; Bio-Rad Laboratories,
Hercules, CA). Blots were developed with Immun-Star
TM AP
Substrate (Bio-Rad Laboratories). We used a-tubulin as an
internal protein loading control, and the band intensities were
defined as described in the footnote of Table 1 when 100 mgo f
protein was loaded per lane.
RT-PCR and quantitative real-time RT-PCR
Total RNA was extracted by using Trizol reagent (Invitrogen,
Carlsbad, CA) and treated with DNA-free
TM (Applied Biosys-
tems). RT-PCR and quantitative real-time RT-PCR were
performed as described previously [10]. The primer sequences
used for all genes are shown in Table S2. For semi-quantitative
RT-PCR, GAPDH expression was used as an internal loading
control, and the band intensities were defined as described in the
footnote of Table 1 under the conditions of 35 PCR cycles.
Dual luciferase reporter assay
The 39-UTR oligonucleotide of SOX2, a 1050 bp fragment
containing the last 36 bps of the SOX2 coding region and the
putative target sites of miR-126 and miR-522, was amplified by
PCR with the following primers: sense, 59-GCGCTCTAGAGC-
CATTAACGGCACACTGCC-39; and anti-sense, 59-GGCCT-
CTAGATACATGGATTCTCGGCAGAC-39. Luciferase con-
structs were obtained by ligating the wild type 39-UTR
oligonucleotide of SOX2 (Wt) or nucleotides with the miR-126
target sites deleted (Del-A, -B or -AB) into the XbaI site of the
pGL4.13 (luc2/SV40) firefly luciferase reporter vector (Promega,
Madison, WI). HEK293T cells were co-transfected using HiPer-
Fect (QIAGEN, Hilden, Germany) with 10 ng of the pGL4.13
vector containing or not containing the 39-UTR sequence (for
normalization of the non-specific effects on pGL4.13-39-UTR
vector of miRNAs), 4 ng of the pGL4.74 (hRluc/TK) renilla
luciferase control vector (for normalization of the transfection
efficiency), and 30 nM Pre-miR-126, Pre-miR-522, SOX2 siRNA,
or Pre-miR-NC. Luciferase activity was measured 24 h after
transfection using a Dual-Luciferase Reporter Assay System
(Promega). Relative luciferase activity was calculated by normal-
izing the firefly luminescence as to the renilla luminescence.
Immunohistochemistory
Paraffin-embedded tissue samples were sectioned, deparaffi-
nized, and then pretreated by autoclaving in 10 mM citric acid
buffer for 15 min to retrieve antigenicity. After the peroxidase
activity had been blocked with 3% H2O2-methanol for 15 min,
the sections were incubated with 10% normal goat serum in PBS
to block nonspecific protein binding, followed by incubation with
primary antibody against SOX2 (1:300; Millipore) at 4uC
overnight. Then, the sections were incubated with horseradish
peroxidase-labeled goat anti-mouse-rabbit antibody (Dako, Car-
pinteria, CA) for 30 min at room temperature, and the signal was
amplified and visualized with diaminobenzidine-chromogen,
followed by counterstaining with hematoxylin. Expression was
considered to be ‘‘positive’’ when 10% or more cancer cells were
stained.
Quantitative real-time RT-PCR of miRNA
Total RNA was extracted by using Trizol reagent (Invitrogen)
and then treated with DNA-free
TM (Applied Biosystems) for cell
lines. On the other hand, paraffin-embedded tissue samples were
sectioned into 10 mm-thick, deparaffinized under RNase-free
condition, and then total RNA was extracted by using Recover-
All
TM Total Nucleic Acid Isolation Kit (Applied Biosystems, Foster
City, CA) according to manufacturer’s instructions. Quantitative
real-time RT-PCR of miRNA was carried out using a TaqMan
Reverse Transcription Kit (Applied Biosystems), TaqMan Micro-
RNA Assays (Applied Biosystems), and a LightCycler TaqMan
Master (Roche Diagnostics, Mannheim, Germany), according to
the manufacturers’ instructions. The expression levels of miRNA
were calculated by the delta-delta Ct method using RNU6B as an
internal control.
Cell proliferation and soft agar colony formation assays
We transfected Pre-miR-126, SOX2 siRNA and Pre-miR-NC
into HSC43 and MKN45 cell lines to give a final concentration of
50 nM by using MicroPorator MP-100. After 48 hours, the
transfected cells were trypsinized, counted and replated in
quadruplicate on 96-well plates (5610
2 cells for HSC43,
2.5610
2 cells for MKN45 per well). Cell proliferation was
evaluated on days 1, 3, 5 and 7 after replating by determining
the number of cells with a Cell Counting Kit-8 (Dojindo,
Kumamoto, Japan), according to the manufacturer’s instructions.
For soft agar colony formation assays, we used a CytoSelect
TM
96-Well In Vitro Tumor Sensitivity Assay Kit (Cell BioLabs, Inc.,
San Diego, CA), according to the manufacturer’s instructions.
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counted and plated in quadruplicate on 96-well plates with Agar
Matrix Layer (2610
3 cells for HSC43, 1610
3 cells for MKN45 per
well). After incubating the cells for 7 to 8 days at 37uC and 5%
CO2, the soft agar in each well was solubilized, and viable cells,
that is, colony-forming cells, were measured with Cell Counting
Kit-8 (Dojindo).
Microarray analysis
Adenovirus (Ad)-SOX2 and control Ad-GFP vectors were
generated as described previously [10], and used to infect NUGC3
cells at the optimum MOI (infectious units/cell) of 20. At 72 h
after infection, total RNA was extracted by using Trizol reagent
(Invitrogen) and then treated with DNA-free
TM (Applied Biosys-
tems). cDNA microarray analysis was conducted by DNA Chip
Research Inc. (Kanagawa, Japan) with Whole Human Genome
oligo DNA arrays (Agilent Technologies, Santa Clara, CA). The
microarray data is Minimum Information About a Microarray
Experiment (MIAME) compliant and has been deposited in a
MIAME compliant database, Gene Expression Omnibus (GEO).
The GEO accession number is GSE23589.
Supporting Information
Table S1 List of genes up- (.2.0-fold) and down-regulated
(,0.5-fold) by SOX2 over-expression.
(XLS)
Table S2 Sequences of RT-PCR primers used in this study.
(XLS)
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